tradingkey.logo
搜尋

Eton Pharmaceuticals Inc

ETON
添加自選
37.500USD
+0.870+2.38%
收盤 07/02, 13:00美東報價延遲15分鐘
1.03B總市值
虧損本益比TTM

Eton Pharmaceuticals Inc

37.500
+0.870+2.38%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+2.38%

5天

+10.36%

1月

+30.75%

6月

+121.76%

今年開始到現在

+121.76%

1年

+167.67%

關鍵數據
36.940今開
37.975最高
525.09K成交量
虧損本益比TTM
20.06本益比動
--股利TTM
1.92%換手率
36.630昨收
36.630最低
14.87M成交額
虧損本益比靜
33.51市淨率
0.00%股息率 TTM
-1.62%ROA
35.66052週最高
1.63量比
-3.82M淨利潤
27.36M總股本
-0.0556每股盈餘TTM
0.88Beta
-5.36%ROE
13.08552週最低
3.67%振幅
60.72%毛利率
1.03B總市值
10.47回報/風險
3.12%風險率

TradingKey Eton Pharmaceuticals Inc股票評分

單位: USD 更新時間: 2026-07-01

操作建議

Eton Pharmaceuticals Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名45/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為45.67。中期看,股價處於上升通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Eton Pharmaceuticals Inc評分

相關信息

行業排名
45 / 157
全市場排名
114 / 4564
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Eton Pharmaceuticals Inc亮點

亮點風險
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
業績高增長
公司營業收入穩步增長,連續3年增長152.67%
業績增長期
公司處於發展階段,最新年度總收入79.95M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入79.95M美元
估值低估
公司最新PE估值-659.17,處於3年歷史低位
機構減倉
最新機構持股15.99M股,環比減少18.71%
ETHSX持倉
明星投資者ETHSX持倉,最新持倉15.71K股

分析師目標

基於 3 分析師
買入
評級
45.667
目標均價
+26.15%
漲幅空間

Eton Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Eton Pharmaceuticals Inc簡介

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
公司代碼ETON
公司Eton Pharmaceuticals Inc
CEOBrynjelsen (Sean E)
網址https://etonpharma.com/

常見問題

Eton Pharmaceuticals Inc(ETON)的當前股價是多少?

Eton Pharmaceuticals Inc(ETON)的當前股價是 36.63。

Eton Pharmaceuticals Inc 的股票代碼是什麼?

Eton Pharmaceuticals Inc的股票代碼是ETON。

Eton Pharmaceuticals Inc股票的52週最高點是多少?

Eton Pharmaceuticals Inc股票的52週最高點是35.66。

Eton Pharmaceuticals Inc股票的52週最低點是多少?

Eton Pharmaceuticals Inc股票的52週最低點是13.09。

Eton Pharmaceuticals Inc的市值是多少?

Eton Pharmaceuticals Inc的市值是1.00B。

現在Eton Pharmaceuticals Inc(ETON)的股票是買入、持有還是賣出?

根據分析師評級,Eton Pharmaceuticals Inc(ETON)的總體評級為買入,目標價格為45.67。

Eton Pharmaceuticals Inc(ETON)股票的每股收益(EPS TTM)是多少

Eton Pharmaceuticals Inc(ETON)股票的每股收益(EPS TTM)是-0.17。